Author:
Maeda Kahoko,Uehara Takeshi,Hosoda Waki,Kuraishi Yasuhiro,Ota Hiroyoshi
Funder
Japan Society for the Promotion of Science
Reference40 articles.
1. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival;Halfdanarson;Ann. Oncol.,2008
2. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis;Ito;J. Gastroenterol.,2015
3. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms;Leoncini;Endocrine,2017
4. Y.J. Ries L.A.G., Keel G.E., Eisner M.P., Lin Y.D., Horner M.-J., Seer Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, Chapter 7 Cancer of the Pancreas Key C, NIH Pub. No. 07-6215 Bethesda, MD, (2007) 59-65.
5. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms;Woll;Int J. Cancer,2014